15 citations
,
February 2021 in “Scientific Reports” RNA aptamers can specifically block FGF5-related cell growth, potentially treating related diseases or hair disorders.
4 citations
,
February 2022 in “International Journal of Dermatology” Porocarcinoma generally has low rates of recurrence, spread to lymph nodes, and death.
March 2025 in “Journal of Clinical Medicine” Low-dose oral minoxidil effectively treats alopecia but can cause side effects like excess hair growth and fluid retention.
1 citations
,
June 2021 in “International journal of pharmaceutical compounding” Minoxidil in FOAMIL is stable for at least 180 days at various concentrations.
34 citations
,
May 2017 in “Lasers in Surgery and Medicine” Combining low-level light therapy and minoxidil 5% is more effective for female hair loss than using either treatment alone.
December 2021 in “International journal of research - granthaalayah” A young woman had a rare, usually non-cancerous tumor on her face that was initially mistaken for a different condition.
15 citations
,
April 2011 in “The journal of investigative dermatology/Journal of investigative dermatology” A3B5 can reduce skin pigmentation and slow melanoma growth.
August 1946 in “Journal of the American Medical Association” Companies agreed to stop false advertising about their products' health benefits.
July 2025 in “Journal of Investigative Dermatology” Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.
June 2024 in “British Journal of Dermatology” Podiatrists need more training to detect foot melanoma early.
January 2026 in “Figshare” Low-dose oral minoxidil improves hair loss and quality of life in women, with manageable side effects.
January 2026 in “Mendeley Data” January 2026 in “Mendeley Data”
April 2024 in “Journal of Cytology” A rare skin tumor with bone formation was successfully removed without recurrence.
January 2026 in “Dermatologic Therapy” Combining microneedling with 5% minoxidil is a safe and effective treatment for female pattern hair loss, promoting significant hair regrowth.
12 citations
,
August 2015 in “Experimental Dermatology” The mineralocorticoid receptor temporarily affects mouse skin development, but the glucocorticoid receptor has a more lasting impact.
8 citations
,
January 2011 in “Experimental and Therapeutic Medicine” Stromal cells in melanoma promote tumor growth and spread.
A patient with Myotonic dystrophy type 1 had multiple tongue hemangiomas and was sensitive to anesthesia.
6 citations
,
June 2012 in “PloS one” A new mRNA variant of the SCF gene in sheep skin produces a shorter, different protein.
January 2026 in “Microchemical Journal” A new method accurately detects minoxidil in hair lotions, revealing discrepancies in labeled content.
2 citations
,
May 2017 in “Zenodo (CERN European Organization for Nuclear Research)” Topical minoxidil 5% can cause erectile dysfunction and decreased libido.
January 2025 in “Journal of Case Reports and Scientific Images” Early diagnosis and treatment are crucial for managing Folliculotropic Mycosis Fungoides on the scalp.
February 2026 in “Expert Opinion on Pharmacotherapy” Low-dose oral and topical minoxidil are recommended for managing hair loss in transplant patients, with specific dosing and timing guidelines.
January 2026 in “Figshare” Low-dose oral minoxidil improves hair loss and quality of life for women, despite mild unwanted hair growth.
2 citations
,
March 2021 in “Journal of Cosmetic Dermatology” Combining platelet-rich plasma therapy with low dose oral minoxidil improved hair growth in men with hair loss, with slightly higher satisfaction at the higher minoxidil dose.
July 2026 in “Jurnal Multidisiplin Dehasen (MUDE)” The hair tonic with moringa and honey is stable and effective for hair loss.
January 1999 in “American Journal of Medical Genetics Part A” The report expanded knowledge of MBTPS1-related disorders by identifying new symptoms.
February 2023 in “International journal of research - granthaalayah” The new microscope method helps study energy from pre-cancerous skin cells.
July 2024 in “Journal of Investigative Dermatology” A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.